530. Bamlanivimab (BAM) for SARS-CoV-2 Infection: Rates and Risk Factors for Hospitalization after Monoclonal Antibody Administration in a High-Risk Population

BACKGROUND: In response to the ongoing COVID-19 pandemic, an emergency use authorization (EUA) was issued for neutralizing antibody therapies including BAM. Licensing trials suggest that use of BAM reduces hospitalizations when compared with placebo (1.6% vs 6.3%). However, the real world impact of...

Descripción completa

Detalles Bibliográficos
Autores principales: Curtin, John M, Costello, Varea H, Custer, Benjamin L, Blaylock, Jason M, Decker, Catherine F, Ressner, Roseanne, Robinson, Sara, Campbell, Wesley R, Blyth, Dana M, Ganesan, Anuradha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643844/
http://dx.doi.org/10.1093/ofid/ofab466.729

Ejemplares similares

Ejemplares similares